From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD125
Clinical data
ATC code
  • none
Legal status
Legal status
  • investigational
CAS Number
  • none
Chemical and physical data
Formula C6492H10060N1724O2028S42
Molar mass 146.0 kg/mol
 NYesY (what is this?)  (verify)

Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3][4]


  1. ^ Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. ^ Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal. 13 (9): 601–604. PMID 20799138. 
  3. ^ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
  4. ^ Nair, Parameswaran; Wenzel, Sally; Rabe, Klaus F.; Bourdin, Arnaud; Lugogo, Njira L.; Kuna, Piotr; Barker, Peter; Sproule, Stephanie; Ponnarambil, Sandhia; Goldman, Mitchell (2017). "Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma". New England Journal of Medicine. 376 (25): 2448. PMID 28530840. doi:10.1056/NEJMoa1703501.